Full history for every metric is available with a Kvantra account
IQ-AI Limited (IQAI.L)
Key financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Operating profit | £m | -0 | -0 | |||||
| Net profit | £m | -1 | -1 | -1 | -1 | -1 | -0 | -0 |
| EPS reported | £ | -0.00 | -0.00 | |||||
| Operating cashflow per share | £ | -0.00 | -0.00 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.00 | -0.00 | |||||
| Free cash flow | £m | -0 | -0 | |||||
| Net debt | £m | -0 | -0 | |||||
| Book value equity | £m | 0 | 0 | |||||
| Book value per share | £ | 0.00 | 0.00 | |||||
| Number of shares | m | 217.95 | 221.71 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 10.09 | 6.73 | |||||
| P/S LTM | x | 4.07 | 2.71 | |||||
| P/FCF LTM | x | -22.41 | -14.95 | |||||
| EV/EBITDA LTM | x | -11.00 | -7.27 | |||||
| EV/Sales LTM | x | 4.00 | 2.64 | |||||
| Earnings Yield LTM | % | -10.72% | -18.19% | |||||
| FCF Yield | % | -4.46% | -6.69% | |||||
| Quality | ||||||||
| ROE | % | -108.12% | -164.60% | |||||
| ROIC | % | -108.26% | -108.26% | |||||
| Operating margin | % | -43.66% | -43.66% | |||||
| Gross margin | % | 91.70% | 91.70% | |||||
| FCF/Sales | % | -18.15% | -18.15% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +23.09% | +23.09% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.20 | 0.20 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -1.75% | -2.63% | |||||
| Net debt/Equity | x | -0.18 | -0.18 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Headquartered in Saint Helier, Jersey, IQ-AI Limited is a technology firm that develops sophisticated software solutions for the healthcare sector, with operations extending to the United States. Its diverse product suite supports medical imaging and diagnostics. Key offerings include IB Clinic, a set of post-processing plug-ins designed to enhance existing image visualization platforms; IB Rad Tech, an engine for streamlining custom clinical workflows; and IB Neuro, which processes MR data to create detailed parametric perfusion maps. The company also provides IB Delta Suite for essential radiology functions such as image co-registration and subtraction. Specialized tools further include IB DCE for analyzing T1-weighted images to derive perfusion and permeability parameters, and IB Diffusion for generating various parameter maps from MR diffusion-weighted data, such as apparent diffusion coefficients and IVIM. Additionally, IB StoneChecker assists clinical decision-making related to kidney stones. Beyond these software innovations, IQ-AI Limited offers valuable consulting services. The company adopted its current name in October 2018, having previously operated as Flying Brands Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
IQ-AI Limited (IQAI.L)
Headquartered in Saint Helier, Jersey, IQ-AI Limited is a technology firm that develops sophisticated software solutions for the healthcare sector, with operations extending to the United States. Its diverse product suite supports medical imaging and diagnostics. Key offerings include IB Clinic, a set of post-processing plug-ins designed to enhance existing image visualization platforms; IB Rad Tech, an engine for streamlining custom clinical workflows; and IB Neuro, which processes MR data to create detailed parametric perfusion maps. The company also provides IB Delta Suite for essential radiology functions such as image co-registration and subtraction. Specialized tools further include IB DCE for analyzing T1-weighted images to derive perfusion and permeability parameters, and IB Diffusion for generating various parameter maps from MR diffusion-weighted data, such as apparent diffusion coefficients and IVIM. Additionally, IB StoneChecker assists clinical decision-making related to kidney stones. Beyond these software innovations, IQ-AI Limited offers valuable consulting services. The company adopted its current name in October 2018, having previously operated as Flying Brands Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free